Fig. 1

Effect of GLP-1(9–36) on infarct size and cardiomyocyte remodelling post-MI. a area at risk and b infarct size assessed 4 weeks following MI (n = 5–6). c Interventricular septal thickness in diastole (IVSD), assessed by echocardiography (n = 11–19). d–e cardiac morphometry normalised to body weight (n = 11–17). f phenylephrine-induced hypertrophy in H9c2 cardiomyoblasts (n = 4). White columns, sham (c–e) or untreated cells (f); black columns, MI (a–e) or phenylephrine-treated cells (f); mean ± SEM. ^**P < 0.01, ^***P < 0.001 versus corresponding sham/untreated control